tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Li PK et al. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. 1990 Adverse Drug React Acute Poisoning Rev pmid:1703724
Jain AB et al. FK 506 dosage in human organ transplantation. 1990 Transplant. Proc. pmid:1689890
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Shapiro R et al. The side effects of FK 506 in humans. 1990 Transplant. Proc. pmid:1689892
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Mieles L et al. Oral glucose tolerance test in liver recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689894
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Staschak S et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. 1990 Transplant. Proc. pmid:1689896
Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. 1990 Transplant. Proc. pmid:1689897
Cadoff EM et al. Assay of FK 506 in plasma. 1990 Transplant. Proc. pmid:1689898
Venkataramanan R et al. Pharmacokinetics of FK 506: preclinical and clinical studies. 1990 Transplant. Proc. pmid:1689899
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Thomson AW FK-506 enters the clinic. 1990 Immunol. Today pmid:1692221
Saitoh Y et al. Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. 1990 Jpn J Surg pmid:1692892
Rosen MK et al. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. 1990 Science pmid:1693013
Thomas FT et al. Comparative efficacy of immunosuppressive drugs in xenografting. 1990 Transplant. Proc. pmid:1693452
Harrison RK and Stein RL Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes. 1990 Biochemistry pmid:1693856
Starzl TE et al. Kidney transplantation under FK 506. 1990 JAMA pmid:1693970
Bierer BE et al. Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. 1990 Transplantation pmid:1694317
Eiras G et al. Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. 1990 Transplantation pmid:1694318
Tze WJ et al. In vitro effects of FK-506 on human and rat islets. 1990 Transplantation pmid:1694319
Kurasawa K et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. 1990 Clin. Immunol. Immunopathol. pmid:1698584
Miyagawa J et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. 1990 Diabetologia pmid:1698679
Lagodzinski Z et al. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. 1990 Immunology pmid:1698713
Mattila PS et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. 1990 EMBO J. pmid:1702384
Kawashima H et al. Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. 1990 Invest. Ophthalmol. Vis. Sci. pmid:1702408
Wilkinson PC and Watson EA FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. 1990 Immunology pmid:1702750
Metcalfe S and Milner J Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. 1990 Immunol. Lett. pmid:1702753
Takada K et al. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. 1990 J. Chromatogr. pmid:1703552
Woo J et al. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. 1990 Immunology pmid:1703987
Akutsu I et al. [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. 1990 Arerugi pmid:1705791
Fung JJ et al. Overview of FK506 in transplantation. 1990 Clin Transpl pmid:1715740
Pugh-Humphreys RG et al. The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. 1990 Immunology pmid:1696242
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Yokota K et al. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival. 1989 Transplant. Proc. pmid:2468209
Inagaki K et al. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation. 1989 Transplant. Proc. pmid:2468210
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Freedman RB Immunosuppression. Convergence of drug action. 1989 Nature pmid:2477712
Siekierka JJ et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. 1989 Nature pmid:2477714
Harding MW et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. 1989 Nature pmid:2477715
Kay JE et al. The mechanism of action of the immunosuppressive drug FK-506. 1989 Cell. Immunol. pmid:2478301
Starzl TE et al. FK 506 for liver, kidney, and pancreas transplantation. 1989 Lancet pmid:2478846
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130